Research progress of immune checkpoint inhibitors in the treatment of glioblastoma

Glioblastoma (GBM) is the most invasive glioma in the central nervous system. Maximum surgical resection, chemotherapy and radiotherapy are currently the standard treatment for GBM. Due to the unique immune environment of the central nervous system, the application of immunotherapy in GBM is facing...

Full description

Saved in:
Bibliographic Details
Main Authors: JIA Xiaorong, ZHANG Gong
Format: Article
Language:zho
Published: Editorial Office of New Medicine 2024-05-01
Series:Yixue xinzhi zazhi
Subjects:
Online Access:https://yxxz.whuznhmedj.com/futureApi/storage/attach/2406/o9E7MrjityHk2SeTlTyNYq8BAgyYODRSNIvoRLZ3.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850243327675334656
author JIA Xiaorong
ZHANG Gong
author_facet JIA Xiaorong
ZHANG Gong
author_sort JIA Xiaorong
collection DOAJ
description Glioblastoma (GBM) is the most invasive glioma in the central nervous system. Maximum surgical resection, chemotherapy and radiotherapy are currently the standard treatment for GBM. Due to the unique immune environment of the central nervous system, the application of immunotherapy in GBM is facing challenges. Immune checkpoint inhibitors (ICIs) is one of the main immunotherapy strategies for GBM. Clarifying the mechanism of ICIs in GBM and developing effective therapeutic targets are of great significance to prolong the survival of GBM patients. In the study, we summarize the research progress of blood-brain barrier, tumor microenvironment, immune cells, ICIs and their combination therapy in GBM to provide reference for GBM immunotherapy.
format Article
id doaj-art-72a72f5c02d54fbf889a64fe5d79bf1c
institution OA Journals
issn 1004-5511
language zho
publishDate 2024-05-01
publisher Editorial Office of New Medicine
record_format Article
series Yixue xinzhi zazhi
spelling doaj-art-72a72f5c02d54fbf889a64fe5d79bf1c2025-08-20T02:00:01ZzhoEditorial Office of New MedicineYixue xinzhi zazhi1004-55112024-05-0134559360210.12173/j.issn.1004-5511.2024010926491Research progress of immune checkpoint inhibitors in the treatment of glioblastomaJIA XiaorongZHANG GongGlioblastoma (GBM) is the most invasive glioma in the central nervous system. Maximum surgical resection, chemotherapy and radiotherapy are currently the standard treatment for GBM. Due to the unique immune environment of the central nervous system, the application of immunotherapy in GBM is facing challenges. Immune checkpoint inhibitors (ICIs) is one of the main immunotherapy strategies for GBM. Clarifying the mechanism of ICIs in GBM and developing effective therapeutic targets are of great significance to prolong the survival of GBM patients. In the study, we summarize the research progress of blood-brain barrier, tumor microenvironment, immune cells, ICIs and their combination therapy in GBM to provide reference for GBM immunotherapy.https://yxxz.whuznhmedj.com/futureApi/storage/attach/2406/o9E7MrjityHk2SeTlTyNYq8BAgyYODRSNIvoRLZ3.pdfglioblastomaimmunotherapyimmunocyteimmune checkpoint inhibitors
spellingShingle JIA Xiaorong
ZHANG Gong
Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
Yixue xinzhi zazhi
glioblastoma
immunotherapy
immunocyte
immune checkpoint inhibitors
title Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
title_full Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
title_fullStr Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
title_full_unstemmed Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
title_short Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
title_sort research progress of immune checkpoint inhibitors in the treatment of glioblastoma
topic glioblastoma
immunotherapy
immunocyte
immune checkpoint inhibitors
url https://yxxz.whuznhmedj.com/futureApi/storage/attach/2406/o9E7MrjityHk2SeTlTyNYq8BAgyYODRSNIvoRLZ3.pdf
work_keys_str_mv AT jiaxiaorong researchprogressofimmunecheckpointinhibitorsinthetreatmentofglioblastoma
AT zhanggong researchprogressofimmunecheckpointinhibitorsinthetreatmentofglioblastoma